On Friday, Novartis AG (NYSE:NVS) agreed to acquire Excellergy Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases.

Novartis Expands Allergy Portfolio

IgE-driven (IgE-mediated) diseases are type I hypersensitivity reactions where immunoglobulin E antibodies trigger mast cells and basophils, causing rapid allergic reactions or chronic inflammation.

The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody, in Phase 1 trial.

Transaction Details And Strategic Rationale

Under the terms of the agreement, Novartis will pay up to $2 billion in upfront and milestone payments to acquire Excellergy.

The transaction is expected to close in the second half of 2026.

The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in allergic disease.

Exl-111 Mechanism ...